SRPT News and Press, Sarepta Therapeutics Inc.

2026-03-07 07:41:45 ET More on Pfizer, Johnson & Johnson, etc. Pfizer: Obesity Hype And Vaccine Policy Shocks The Sun Will Shine On Moderna Again - Initiating With A Buy Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom J&J subsidi...

2026-03-05 14:49:43 ET Investment Overview The stock of PepGen Inc. ( PEPG ) is down >20% in early trading today, after the company released its Q4 and full-year 2025 earnings, and shared the news that the FDA had placed a partial clinical hold on its FREEDOM2-DM1...

2026-03-03 17:32:18 ET Sarepta Therapeutics, Inc. (SRPT) TD Cowen 46th Annual Health Care Conference March 3, 2026 1:50 PM EST... Read the full article on Seeking Alpha For further details see: Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Co...

2026-03-03 14:03:33 ET Andrew Tsai from Jefferies issued a price target of $30.00 for SRPT on 2026-03-03 17:00:00. The adjusted price target was set to $30.00. At the time of the announcement, SRPT was trading at $15.976. The overall price target consensus is at $21.57 w...

– Applications for the 2026-2027 academic year will be accepted until May 15, 2026 – Scholarships will be awarded to up to 20 individuals living with Duchenne muscular dystrophy and up to five siblings of individuals living with Duchenne Sarepta Therape...

Several abstracts, including a late-breaking podium presentation and posters, bring forward accumulating long-term efficacy, safety and caregiver-reported insights that deepen understanding of dystrophin restoration and its impact in Duchenne Sarepta Therapeutics, Inc. (NASDAQ:SRP...

2026-02-26 00:10:48 ET Read the full article on Seeking Alpha For further details see: Sarepta Therapeutics begins search for CEO as Douglas Ingram announces retirement; shares down

2026-02-25 20:28:37 ET More on Sarepta Therapeutics Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy - Slideshow ...

2026-02-25 20:27:48 ET Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call February 25, 2026 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript

2026-02-25 18:55:37 ET Image source: The Motley Fool. Feb. 25, 2026 at 4:30 p.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading